The FDA approved a higher-dose version of Novo Nordisk’s Wegovy as semaglutide patents expire in major markets including India and China—setting up broader access abroad and a new dosing option in the U.S. Clinically, that means intensifying competition with Lilly while billions of patients may soon see prices fall from $100–$200/month toward ~$15/month in some countries.

The move

• The FDA cleared a higher-dose Wegovy formulation, a Novo Nordisk bid to regain momentum against Lilly’s Zepbound.

• Outside the U.S., semaglutide patent protection expires today in some of the world’s most populous countries, including India and China.

• Analysts expect rapid generic entry: ~50 generic semaglutide brands could launch in India alone, some as soon as this weekend; additional waves are expected in China, Brazil, Turkey, South Africa, and Canada within months.

Why it Matters for Care

• More dosing headroom in the U.S.: a higher-dose Wegovy option can change titration strategies and may affect real-world weight-loss durability for patients who plateau on existing doses.

• Global access surge: in China and India—where 1.1+ billion adults are overweight or have diabetes—generic availability could expand treatment for patients priced out of brand products.

• Expect cross-border clinical questions: patients may ask about “generic semaglutide” quality, interchangeability, and monitoring needs vs. branded Ozempic/Wegovy.

Between the Lines

• This is a two-front fight for Novo: defend U.S. share with product iteration (higher dose) while losing pricing power abroad as patents lapse.

• Price is the accelerant: Ozempic/Wegovy can run $100–$200/month in China/India, but analysts see a path to ~$15/month as manufacturers compete.

• Novo’s pre-expiry moves—seeking to block generics in India/China/Brazil and cutting prices in China/India—signal it expects volume to shift quickly once generics hit.

What to Watch

• U.S. prescribing and coverage: whether payers treat the higher-dose Wegovy as meaningfully distinct for authorization and step-therapy decisions.

• Regulatory and legal aftershocks abroad: any late-breaking court or agency actions that slow (or accelerate) generic launches in India, China, and Brazil.

• Market-share data: whether Novo’s higher-dose strategy blunts Lilly’s momentum after Lilly reported its experimental diabetes shot outperformed all diabetes drugs in a recent study.

Source: Morning Brew